Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLIM2402
- Development stage
- Preclinical
- Lead developer
- Samik Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SLIM2402 is a small molecule therapeutic candidate currently under development by Samik Pharmaceutical. It is classified as an "improved new drug" (incrementally modified drug) in South Korea, a regulatory category for products that offer improvements in safety, efficacy, or convenience over existing reference drugs. SLIM2402 is being investigated for use in cancer and immune adjuvant therapy and is currently in the preclinical (basic research) stage of development. As an improved new drug, it likely represents a new formulation, salt, or delivery method of a known active pharmaceutical ingredient intended to enhance therapeutic outcomes in oncology settings.
Beyond the preview
Go deeper on SLIM2402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLIM2402.